Preview
The recently announced findings of the Coronary Primary Prevention Trial unequivocally confirmed what investigators have long believed—that risk of coronary artery disease can be reduced by lowering the level of serum cholesterol. Now the task confronting physicians is to determine what constitutes a “normal” level of cholesterol, how lipid lowering can best be achieved, and who is a likely candidate for treatment. Dr Glatter presents his recommendations on this timely subject in the following review.